The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...

As of last year, RSV vaccination with Abrysvo has been recommended for pregnant women in the United States from 32 to 36 ...